Allermi's $3.5 million seed funding was led by Nelstone Ventures and included participation from FourSight Capital Partners. The company will use the money to expand nationally.
Aerin Medical just closed a $16.7 million Series C to craft an interesting solution to the issue - using non-ablative radiofrequency energy to target and remodel the structural and mucosal tissues that cause nasal congestion.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.